UTAH DEPARTMENT OF HEALTH
STATE MEDICAID PHARMACY AND THERAPEUTICS COMMITTEE
Thursday, January 20, 2011
7:00 a.m. to 8:30 a.m.
Cannon Health Building			
Room 114

                                     AGENDA

Please note that persons who wish to address the P&T Committee may contact Lisa Hulbert  (lhulbert@utah.gov) at least 7 calendar days prior to the meeting.  Comments from visitors, while welcome, may be limited due to time constraints

1. 	Review and Approval of Minutes..............................................................................Chair

2.	Housekeeping.....................................................................................	Lisa V. Hulbert, R.Ph.				

3.	DUR Board Update.........................................................................Robyn Seely, PharmD.		

4.	Contraceptives, oral/vaginal/transdermal................................Melissa Archer, PharmD.

Included agents: Aleesse, Cyclessa, Demulen, Depo-provera, Estrostep, Levlite, Lo/Ovral, Loestrin/FE, Mircette, Nordette, Nor-Q-D, Nuvaring, Ortho-Micronor, Ortho-Tri-Cyclen, Ortho-Evra, Ortho-Cept, Ortho-Cyclen, Ortho-Novum, Ovcon, Seasonale, Tri-Norinyl, Triphasal and all approved generics.
Documents: UU class review, UU list of available agents and dosage forms

Public comment that responds to the materials presented by the College of Pharmacy @University of Utah is most helpful.  The foundation documents used for most reviews are prepared by the Oregon Evidence-based Practice Center or the Drug Information Service and are posted in advance on the P&T Committee website

Manufacturers are requested to submit any additional materials they would like reviewed as part of the process to:  

Dr. Gary Oderda
College of Pharmacy
30 South 2000 East
SLC, UT 84112-5820

All materials must be clearly labeled that they are submitted for consideration as part of the state of Utah Medicaid Preferred Drug List Program review process.  Materials must be received at least 60 days before the scheduled review date.  Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible) after the Oregon monograph was prepared, unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search.